Skip to main content

Table 4 Response rate and control rate of sitting systolic blood pressure, and goal attainment rate of low-density lipoprotein cholesterol by each treatment. (Analysis of per-protocol set)

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

  Summary of each treatment FMS/RSV vs FMS FMS/RSV vs RSV
  FMS/RSV FMS RSV Difference(SE) P-valued Difference(SE) P-valued
  N = 35 N = 36) N = 37 (95% C.I.)   (95% C.I.)  
siSBP        
 Response ratea, n (%) 26 (74.29) 23 (63.89) 15 (40.54) 10.40 (10.89)   33.75 (10.94)  
  95% CI (59.81, 88.77) (48.20, 79.58) (24.72, 56.36) (−10.95, 31.75) 0.390 (12.30, 55.19) 0.010
 Control rateb, n (%) 26 (74.29) 23 (63.89) 13 (35.14) 10.40 (10.89)   39.15 (10.78)  
  95% CI (59.81, 88.77) (48.20, 79.58) (19.75, 50.52) (−10.95, 31.75) 0.358 (18.03, 60.28) 0.003
LDL-C        
 Goal attainment ratec, n (%) 33 (94.29) 7 (19.44) 34 (91.89) 74.84 (7.67)   2.39 (5.96)  
  95% CI (86.60, 100.00) (6.52, 32.37) (83.10, 100.00) (59.80, 89.88) <0.001 (−21.13, 25.12) 0.082
  1. FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, siSBP sitting systolic blood pressure, LDL-C low-density lipoprotein cholesterol, CI confidence interval, SE standard error
  2. aResponse Rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg or Chang from Baseline of siSBP at Week 8 ≥ 20 mmHg
  3. bControl rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg
  4. cGoal attainment rate of LDL-C: proportion of the subjects whose LDL-C < 100 mg/dL (high risk), LDL-C < 130 mg/dL (moderate high or moderate risk), LDL-C < 160 mg/dL (low risk)
  5. dComparison between combination therapy and monotherapy was analyzed by Logistic regression model adjusted for baseline values, age, and gender, smoking status